Literature DB >> 2158040

Alterations in growth properties of human papilloma virus type 16 immortalised human cervical keratinocyte cell line correlate with amplification and overexpression of c-myc oncogene.

T Crook1, I Greenfield, J Howard, M Stanley.   

Abstract

Clinical and epidemiological data support a role for human papilloma virus (HPV) type 16 in the pathogenesis of cervical carcinoma. The W12 cell line contains HPV16 sequences, predominantly as a high copy number episome, and is immortalised in vitro, but non-tumourigenic. A morphologically distinct sub-line of the parental W12 cell line was isolated which displayed increased growth rate, increased capacity for self-renewal and increased resistance to differentiation in comparison with the parental W12 cell line. The structure and expression of the HPV16 sequences was virtually identical in the two cell lines. However, expression of the c-myc proto-oncogene was elevated in the morphologically distinct sub-line, and this was associated with amplification, but not rearrangement, of the c-myc locus. Karyotype analysis demonstrated that amplification of the c-myc locus was a result of duplication of the long arm of chromosome eight.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158040

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  3 in total

1.  Evaluation of the prognostic significance of nm23/NDP kinase and cathepsin D in anal carcinomas. An immunohistochemical study.

Authors:  R Holm; G Tanum
Journal:  Virchows Arch       Date:  1996-05       Impact factor: 4.064

2.  C-myc oncogene expression in ocular melanomas.

Authors:  J A Royds; R M Sharrard; M A Parsons; J Lawry; R Rees; D Cottam; B Wagner; I G Rennie
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

3.  C-myc oncogene expression in anal squamous neoplasia.

Authors:  O A Ogunbiyi; J H Scholefield; K Rogers; F Sharp; J H Smith; S V Polacarz
Journal:  J Clin Pathol       Date:  1993-01       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.